EUVIMEDEUVIMED entdecken
Open Access

In Vivo Studies of [ 161 Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression

Sigrid Cold, Pragalath Sadasivam, Mette M Wessel, Myrto Ischyropoulou, Jesper Fonslet, Trine B Engel, Carsten H Nielsen, Andreas Kjaer, Lotte K Kristensen

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.269741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Sigrid Cold und 8 weiteren Autor:innen. Beteiligte Einrichtung: Minerva Imaging ApS, Ølstykke, Denmark. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) has emerged as attractive for targeted radionuclide therapy of HER2-expressing breast cancer. The present study aimed to investigate the image-derived biodistribution, tolerability, and efficacy of [161Tb]Tb-trastuzumab as a potential therapeutic alternative or supplement to trastuzumab and trastuzumab deruxtecan in HER2-expressing tumors.

Methods

Trastuzumab was functionalized with DOTA by non-site-specific conjugation and radiolabeled with 161Tb. In vitro assays were performed to evaluate binding affinity and immunoreactivity of [161Tb]Tb-trastuzumab. The influence of mass dose on the biodistribution of [161Tb]Tb-trastuzumab was assessed in mice bearing subcutaneous BT474 tumors by SPECT/CT imaging performed 4, 24, 72, and 168 h after injection of 20 MBq of [161Tb]Tb-trastuzumab labeled at 3 specific activities. Tolerability was evaluated with escalating doses of 5, 10, and 20 MBq of [161Tb]Tb-trastuzumab, and the efficacy of [161Tb]Tb-trastuzumab was compared with that of the vehicle, trastuzumab, and trastuzumab deruxtecan groups.

Results

Functionalization and radiolabeling resulted in a radiochemical yield of 97% ± 2% and a radiochemical purity above 99%. The binding affinity of functionalized and native trastuzumab was 0.83 and 0.39 nM, respectively, with an immunoreactive fraction of 89%. SPECT/CT imaging demonstrated peak tumor uptake 72 h after injection, with tumor uptake of 10.8 ± 1.1, 12.8 ± 2.2, and 6.3 ± 0.03 %ID/g of tissue for mice dosed with 0.5, 0.05, and 0.005 MBq/µg, respectively. Radiotoxicity was evident in mice dosed with 20 MBq of [161Tb]Tb-trastuzumab, whereas 5 and 10 MBq of [161Tb]Tb-trastuzumab were well tolerated. Antitumor efficacy was observed in mice dosed with 10 MBq of [161Tb]Tb-trastuzumab, which presented tumor volumes statistically significantly smaller than those of the vehicle group 104 d after treatment (P = 0.0007).

Conclusion

Functionalization and radiolabeling did not affect binding affinity. Biodistribution of [161Tb]Tb-trastuzumab revealed high tumor uptake of more than 10 %ID/g of tissue, peaking at 72 h. [161Tb]Tb-trastuzumab in doses of up to 10 MBq was tolerated and highly effective at inhibiting tumor growth (P = 0.0007). These results support the potential of [161Tb]Tb-trastuzumab as an attractive treatment option for HER2-expressing cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabErb-b2 Receptor Tyrosine KinasesBreast NeoplasmsRadiopharmaceuticalsGene Expression Regulation, NeoplasticAnimalsMiceFemaleHumansTissue DistributionCell Line, TumorSingle Photon Emission Computed Tomography Computed TomographyBiological TransportCell Proliferation

Stichwörter der Autor:innen

HER2breast cancermolecular imagingradionuclide therapytheranostics

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesRadiopharmaceuticalsERBB2 protein, human

Autor:innen und Institutionen

  • Minerva Imaging ApS, Ølstykke, Denmark.
  • Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; and.
  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Minerva Imaging ApS, Ølstykke, Denmark; lkk@minervaimaging.com.

Zitieren

APA

Cold, S., Sadasivam, P., Wessel, M. M., Ischyropoulou, M., Fonslet, J., Engel, T. B., Nielsen, C. H., Kjaer, A., & Kristensen, L. K. (2026). In Vivo Studies of [ 161 Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269741

Vancouver

Cold S, Sadasivam P, Wessel MM, Ischyropoulou M, Fonslet J, Engel TB, et al. In Vivo Studies of [ 161 Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.269741

BibTeX
@article{Cold2026,
  author = {Cold, Sigrid and Sadasivam, Pragalath and Wessel, Mette M and Ischyropoulou, Myrto and Fonslet, Jesper and Engel, Trine B and Nielsen, Carsten H and Kjaer, Andreas and Kristensen, Lotte K},
  title = {In Vivo Studies of [ 161 Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.269741}
}
Kostenlos starten →